This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (57)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Neurology  • Stroke  • Cardiovascular System  • Evidence-Based Medicine  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review and Meta-analysis

Jaapjan D. Snoep, MSc; Marcel M. C. Hovens, MD; Jeroen C. J. Eikenboom, MD, PhD; Johanna G. van der Bom, MD, PhD; Menno V. Huisman, MD, PhD

Arch Intern Med. 2007;167(15):1593-1599.

Background  The risk of recurrence of cardiovascular events among patients using aspirin (acetylsalicylic acid) for secondary prevention of such events remains high. Persistent platelet reactivity despite aspirin therapy, a laboratory-defined phenomenon called aspirin resistance (hereinafter, laboratory aspirin resistance), might explain this in part, but its actual contribution to the risk remains unclear. The objective of this study was to systematically review all available evidence on whether laboratory aspirin resistance is related to a higher risk of cardiovascular recurrent events.

Methods  Using a predefined search strategy, we searched electronic databases. To be included in our analysis, articles had to report on patients who used aspirin for secondary cardiovascular prevention, had to contain a clear description of a method to establish the effects of aspirin on platelet reactivity, and had to report recurrence rates of cardiovascular events. Odds ratios of cardiovascular outcome of eligible studies were pooled in a random-effects model.

Results  We included 15 full-text articles and 1 meeting abstract. Fifteen of these studies revealed an adverse association between laboratory aspirin resistance and occurrence of cardiovascular events. The pooled odds ratio of all cardiovascular outcomes was 3.8 (95% confidence interval, 2.3-6.1) for laboratory aspirin resistance.

Conclusion  This systematic review and meta-analysis shows that patients biochemically identified as having laboratory aspirin resistance are more likely to also have "clinical resistance" to aspirin because they exhibit significantly higher risks of recurrent cardiovascular events compared with patients who are identified as (laboratory) aspirin sensitive.

Author Affiliations: Departments of General Internal Medicine and Endocrinology (Mr Snoep and Drs Hovens and Huisman), Hematology (Dr Eikenboom), and Clinical Epidemiology (Mr Snoep and Dr van der Bom), Leiden University Medical Center, Leiden, the Netherlands.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events
Pierre Fontana and Jean-Luc Reny
Arch Intern Med. 2008;168(5):549-550.
EXTRACT | FULL TEXT  

Is Aspirin Resistance Due to Noncompliance?
James E. Dalen
Arch Intern Med. 2008;168(5):550.
EXTRACT | FULL TEXT  

Is Aspirin Resistance Due to Noncompliance?—Reply
Jaapjan D. Snoep, Marcel M. C. Hovens, Jeroen C. J. Eikenboom, Johanna G. van der Bom, and Menno V. Huisman
Arch Intern Med. 2008;168(5):550.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspirin "resistance" and its impact on cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured
Brister and Buchanan
Heart 2009;95:1223-1224.
FULL TEXT  

Aspirin resistance testing not ready for "prime time"
Hjemdahl
Heart 2009;95:1220-1222.
FULL TEXT  

Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Chen et al.
Circulation 2009;119:3207-3214.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
Angiolillo
Diabetes Care 2009;32:531-540.
FULL TEXT  

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance".
Santilli et al.
J Am Coll Cardiol 2009;53:667-677.
ABSTRACT | FULL TEXT  

Aspirin resistance transient laboratory finding or important clinical entity?
Lev
J Am Coll Cardiol 2009;53:678-680.
FULL TEXT  

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Kuliczkowski et al.
Eur Heart J 2009;30:426-435.
ABSTRACT | FULL TEXT  

Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up
Marcucci et al.
Circulation 2009;119:237-242.
ABSTRACT | FULL TEXT  

Should we monitor platelet function during antiplatelet therapy?
Hjemdahl
Heart 2008;94:685-687.
FULL TEXT  

The implications of aspirin resistance in renal failure
Thachil
NDT Plus 2008;1:192-193.
FULL TEXT  

Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events
Fontana and Reny
Arch Intern Med 2008;168:549-550.
FULL TEXT  

Is Aspirin Resistance Due to Noncompliance?
Dalen
Arch Intern Med 2008;168:550-550.
FULL TEXT  

Is Aspirin Resistance Due to Noncompliance?--Reply
Snoep et al.
Arch Intern Med 2008;168:550-550.
FULL TEXT  

Aspirin Resistance: Biological and Clinical Implications
Tseeng and Arora
J CARDIOVASC PHARMACOL THER 2008;13:5-12.
ABSTRACT  

Aspirin resistance in cardiovascular disease
Biondi-Zoccai and Lotrionte
BMJ 2008;336:166-167.
FULL TEXT  

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis
Krasopoulos et al.
BMJ 2008;336:195-198.
ABSTRACT | FULL TEXT  

Testing antiplatelet therapy
Gachet and Aleil
Eur Heart J Suppl 2008;10:A28-A34.
ABSTRACT | FULL TEXT